If you liked this article you might like

Big Pharma Spends Millions to Keep Prices High for California Agencies
Mylan Is Done Leaning on EpiPen Sales and That Could be a Big Problem
Why EpiPen, Why Now? Analysts Explain the Timing of Mylan's Trouble
A Backlash Materializes Against Soaring EpiPen Prices